Rocket Lab Corporation enters the final stretch of August with a sharp week-behind it and options traders the most defensively positioned they have been all year.
The stock fell 15.5% over the past five sessions to close at $66.91, extending a retreat from levels above $85 where CEO Peter Beck was selling heavily in early July. That price action is doing real work in the options market. The put/call ratio jumped to 0.82 — nearly 2.5 standard deviations above its 20-day average of 0.71 — and is now within a whisker of the 52-week high of 0.85. That is the clearest sign in months that traders are paying up for downside protection rather than chasing the upside.
Short positioning tells a noticeably less alarming story. Short interest has been declining steadily, dropping about 5% on the week and more than 9% over the past month to sit at 8.1% of the free float — elevated in absolute terms but moving in the wrong direction for the bears. Borrow conditions do nothing to discourage fresh shorts either: cost to borrow runs at a negligible 0.43%, and availability is loose at roughly 329% of outstanding short interest, meaning there are more than three shares available to borrow for every one already borrowed. The ORTEX short score has also drifted lower through August, easing from above 53 to 50.9, indicating a gradual reduction in short-side conviction. The setup is not a squeeze candidate — it is simply a stock where short sellers have been trimming into the weakness, not pressing it.
The broader peer cohort confirms this week's move was not idiosyncratic. FLY fell 14.8% over the same period, LUNR dropped 14.0%, and VOYG was the worst of the group, down 18.3%. The sell-off looks sector-wide rather than company-specific. One outlier: HOVR held near flat, off just 0.5% on the week. Against that backdrop, Rocket Lab's 15.5% decline is painful but broadly in line with the peer average.
The institutional base appears committed. BlackRock added 2.6 million shares in the most recently reported period, and both JPMorgan Asset Management and UBS lifted positions meaningfully. Invesco added over 14.5 million shares as of June 30 — the largest institutional move in the holder table. That kind of accumulation from passive and active managers suggests the pullback has not triggered visible institutional selling, though the data lags the current price action by one to two months.
The founder selling from early July is worth keeping in focus. Peter Beck sold approximately $155 million worth of stock across July 7 and July 8 at prices ranging from $81 to $89 — well above the current $66.91. Those were scheduled or planned sales rather than a reaction to any specific event, but the volume is notable and the stock is now trading materially below those execution prices. Meanwhile, the next earnings date lands on November 10, with the most recent quarterly result producing a 3.4% single-day decline and near-flat performance over the following five days — a muted reaction relative to the volatility the stock has shown in the weeks since.
What to watch: whether the put/call ratio pulls back toward its historical average as the week's price shock fades, or whether it holds near the 52-week high — that would indicate option traders view the current level as a staging point rather than a floor.
See the live data behind this article on ORTEX.
Open RKLB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
